Anti-CD30 immunotoxins with native and recombinant dianthin 30

Andrea Bolognesi, Pier Luigi Tazzari, Guiseppe Legname, Fabiola Olivieri, Daniela Modena, Roberto Conte, Fiorenzo Stirpe

Research output: Contribution to journalArticle

Abstract

Immunotoxins were prepared with a Ber-H2 (anti-CD30) monoclonal antibody and native or recombinant dianthin 30, a ribosome-inactivating protein from Dianthus caryophyllus (carnation). Both immunotoxins selectively inhibited protein synthesis by CD30+ cell lines D430B (lymphoblastoid, infected with Epstein-Barr virus). L428 and L540 (both from Hodgkin's lymphoma). IC50 values (concentrations, as dianthin, causing 50% inhibition) ranged from 324 pM to 479 pM (immunotoxin with native dianthin 30) or from 45 pM to 182 pM (immunotoxin with recombinant dianthin 30). The effect of either immunotoxin on protein synthesis by the CD30- cell line K562 (from a chronic myeloid leukaemia) was not different from that of free dianthin (IC50 higher than nM).

Original languageEnglish
Pages (from-to)109-114
Number of pages6
JournalCancer Immunology, Immunotherapy
Volume40
Issue number2
DOIs
Publication statusPublished - Mar 1995

Fingerprint

Immunotoxins
Dianthus
Inhibitory Concentration 50
Ribosome Inactivating Proteins
Cell Line
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Human Herpesvirus 4
Hodgkin Disease
Proteins
Monoclonal Antibodies

Keywords

  • Dianthin
  • Hodgkin's lymphoma
  • Immunotoxin
  • Ribosome-inactivating protein

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Bolognesi, A., Tazzari, P. L., Legname, G., Olivieri, F., Modena, D., Conte, R., & Stirpe, F. (1995). Anti-CD30 immunotoxins with native and recombinant dianthin 30. Cancer Immunology, Immunotherapy, 40(2), 109-114. https://doi.org/10.1007/BF01520292

Anti-CD30 immunotoxins with native and recombinant dianthin 30. / Bolognesi, Andrea; Tazzari, Pier Luigi; Legname, Guiseppe; Olivieri, Fabiola; Modena, Daniela; Conte, Roberto; Stirpe, Fiorenzo.

In: Cancer Immunology, Immunotherapy, Vol. 40, No. 2, 03.1995, p. 109-114.

Research output: Contribution to journalArticle

Bolognesi, A, Tazzari, PL, Legname, G, Olivieri, F, Modena, D, Conte, R & Stirpe, F 1995, 'Anti-CD30 immunotoxins with native and recombinant dianthin 30', Cancer Immunology, Immunotherapy, vol. 40, no. 2, pp. 109-114. https://doi.org/10.1007/BF01520292
Bolognesi, Andrea ; Tazzari, Pier Luigi ; Legname, Guiseppe ; Olivieri, Fabiola ; Modena, Daniela ; Conte, Roberto ; Stirpe, Fiorenzo. / Anti-CD30 immunotoxins with native and recombinant dianthin 30. In: Cancer Immunology, Immunotherapy. 1995 ; Vol. 40, No. 2. pp. 109-114.
@article{0aa56ee9f75b4789a87b14e76bf4b114,
title = "Anti-CD30 immunotoxins with native and recombinant dianthin 30",
abstract = "Immunotoxins were prepared with a Ber-H2 (anti-CD30) monoclonal antibody and native or recombinant dianthin 30, a ribosome-inactivating protein from Dianthus caryophyllus (carnation). Both immunotoxins selectively inhibited protein synthesis by CD30+ cell lines D430B (lymphoblastoid, infected with Epstein-Barr virus). L428 and L540 (both from Hodgkin's lymphoma). IC50 values (concentrations, as dianthin, causing 50{\%} inhibition) ranged from 324 pM to 479 pM (immunotoxin with native dianthin 30) or from 45 pM to 182 pM (immunotoxin with recombinant dianthin 30). The effect of either immunotoxin on protein synthesis by the CD30- cell line K562 (from a chronic myeloid leukaemia) was not different from that of free dianthin (IC50 higher than nM).",
keywords = "Dianthin, Hodgkin's lymphoma, Immunotoxin, Ribosome-inactivating protein",
author = "Andrea Bolognesi and Tazzari, {Pier Luigi} and Guiseppe Legname and Fabiola Olivieri and Daniela Modena and Roberto Conte and Fiorenzo Stirpe",
year = "1995",
month = "3",
doi = "10.1007/BF01520292",
language = "English",
volume = "40",
pages = "109--114",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Anti-CD30 immunotoxins with native and recombinant dianthin 30

AU - Bolognesi, Andrea

AU - Tazzari, Pier Luigi

AU - Legname, Guiseppe

AU - Olivieri, Fabiola

AU - Modena, Daniela

AU - Conte, Roberto

AU - Stirpe, Fiorenzo

PY - 1995/3

Y1 - 1995/3

N2 - Immunotoxins were prepared with a Ber-H2 (anti-CD30) monoclonal antibody and native or recombinant dianthin 30, a ribosome-inactivating protein from Dianthus caryophyllus (carnation). Both immunotoxins selectively inhibited protein synthesis by CD30+ cell lines D430B (lymphoblastoid, infected with Epstein-Barr virus). L428 and L540 (both from Hodgkin's lymphoma). IC50 values (concentrations, as dianthin, causing 50% inhibition) ranged from 324 pM to 479 pM (immunotoxin with native dianthin 30) or from 45 pM to 182 pM (immunotoxin with recombinant dianthin 30). The effect of either immunotoxin on protein synthesis by the CD30- cell line K562 (from a chronic myeloid leukaemia) was not different from that of free dianthin (IC50 higher than nM).

AB - Immunotoxins were prepared with a Ber-H2 (anti-CD30) monoclonal antibody and native or recombinant dianthin 30, a ribosome-inactivating protein from Dianthus caryophyllus (carnation). Both immunotoxins selectively inhibited protein synthesis by CD30+ cell lines D430B (lymphoblastoid, infected with Epstein-Barr virus). L428 and L540 (both from Hodgkin's lymphoma). IC50 values (concentrations, as dianthin, causing 50% inhibition) ranged from 324 pM to 479 pM (immunotoxin with native dianthin 30) or from 45 pM to 182 pM (immunotoxin with recombinant dianthin 30). The effect of either immunotoxin on protein synthesis by the CD30- cell line K562 (from a chronic myeloid leukaemia) was not different from that of free dianthin (IC50 higher than nM).

KW - Dianthin

KW - Hodgkin's lymphoma

KW - Immunotoxin

KW - Ribosome-inactivating protein

UR - http://www.scopus.com/inward/record.url?scp=0028919064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028919064&partnerID=8YFLogxK

U2 - 10.1007/BF01520292

DO - 10.1007/BF01520292

M3 - Article

C2 - 7882380

AN - SCOPUS:0028919064

VL - 40

SP - 109

EP - 114

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -